Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Capital Expenditures (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Capital Expenditures for 8 consecutive years, with $674000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures rose 54.94% year-over-year to $674000.0, compared with a TTM value of $2.1 million through Sep 2025, up 133.55%, and an annual FY2024 reading of $1.2 million, down 57.84% over the prior year.
  • Capital Expenditures was $674000.0 for Q3 2025 at Bicycle Therapeutics, up from $498000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $9.8 million in Q2 2022 and bottomed at -$496000.0 in Q3 2021.
  • Average Capital Expenditures over 5 years is $1.4 million, with a median of $502000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures crashed 622.11% in 2021, then soared 5630.41% in 2022.
  • Year by year, Capital Expenditures stood at $1.7 million in 2021, then dropped by 16.4% to $1.4 million in 2022, then plummeted by 96.48% to $51000.0 in 2023, then skyrocketed by 621.57% to $368000.0 in 2024, then soared by 83.15% to $674000.0 in 2025.
  • Business Quant data shows Capital Expenditures for BCYC at $674000.0 in Q3 2025, $498000.0 in Q2 2025, and $604000.0 in Q1 2025.